摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S,3R,4R,7S)-3-(4-N-benzoylcytosin-1-yl)-7-benzyloxy-1-benzyloxymethyl-2,5-dioxabicyclo[2.2.1]heptane | 206055-65-4

中文名称
——
中文别名
——
英文名称
(1S,3R,4R,7S)-3-(4-N-benzoylcytosin-1-yl)-7-benzyloxy-1-benzyloxymethyl-2,5-dioxabicyclo[2.2.1]heptane
英文别名
(1S,3R,4R,7S)-7-Benzyloxy-1-benzyloxymethyl-3-(4-N-benzoylcytosin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane;N-[2-oxo-1-[(1S,3R,4R,7S)-7-phenylmethoxy-1-(phenylmethoxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]pyrimidin-4-yl]benzamide
(1S,3R,4R,7S)-3-(4-N-benzoylcytosin-1-yl)-7-benzyloxy-1-benzyloxymethyl-2,5-dioxabicyclo[2.2.1]heptane化学式
CAS
206055-65-4
化学式
C31H29N3O6
mdl
——
分子量
539.588
InChiKey
WIFLYDHNKRLTQS-XQGSQPOPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    40
  • 可旋转键数:
    10
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    98.7
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (1S,3R,4R,7S)-3-(4-N-benzoylcytosin-1-yl)-7-benzyloxy-1-benzyloxymethyl-2,5-dioxabicyclo[2.2.1]heptane 在 palladium on activated charcoal 1,4-环己二烯 作用下, 以 甲醇 为溶剂, 反应 72.0h, 以36%的产率得到4-amino-1-[(1S,3R,4R,7S)-7-hydroxy-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-1,2-dihydropyrimidin-2-one
    参考文献:
    名称:
    LNA(锁定核酸):腺嘌呤,胞嘧啶,鸟嘌呤,5-甲基胞嘧啶,胸腺嘧啶和尿嘧啶双环核苷单体的合成,寡聚化和前所未有的核酸识别
    摘要:
    由2'- O,4'- C-亚甲基双环核苷单体组成的LNA(锁定核酸)被有效合成,并评估了其对六种不同核碱基(腺嘌呤,胞嘧啶,鸟嘌呤,5-甲基胞嘧啶,胸腺嘧啶)的核酸识别潜力和尿嘧啶。当评估部分或完全修饰的LNA的混合序列时,双链体对DNA和RNA的热稳定性出现了前所未有的提高(每个修饰+3至+8°C)。错配序列的研究表明,与相应的未修饰参考链相比,LNA遵循具有普遍提高的选择性的Watson-Crick碱基配对规则。
    DOI:
    10.1016/s0040-4020(98)00094-5
  • 作为产物:
    参考文献:
    名称:
    LNA(锁定核酸):腺嘌呤,胞嘧啶,鸟嘌呤,5-甲基胞嘧啶,胸腺嘧啶和尿嘧啶双环核苷单体的合成,寡聚化和前所未有的核酸识别
    摘要:
    由2'- O,4'- C-亚甲基双环核苷单体组成的LNA(锁定核酸)被有效合成,并评估了其对六种不同核碱基(腺嘌呤,胞嘧啶,鸟嘌呤,5-甲基胞嘧啶,胸腺嘧啶)的核酸识别潜力和尿嘧啶。当评估部分或完全修饰的LNA的混合序列时,双链体对DNA和RNA的热稳定性出现了前所未有的提高(每个修饰+3至+8°C)。错配序列的研究表明,与相应的未修饰参考链相比,LNA遵循具有普遍提高的选择性的Watson-Crick碱基配对规则。
    DOI:
    10.1016/s0040-4020(98)00094-5
点击查看最新优质反应信息

文献信息

  • Oligonucleotide analogues
    申请人:Wengel Jesper
    公开号:US20050287566A1
    公开(公告)日:2005-12-29
    The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.
    本发明涉及新型的双环和三环核苷酸和核苷酸类似物,以及包含这些元素的寡核苷酸。这些核苷酸类似物,即锁定核苷酸类似物(LNAs),能够为寡核苷酸提供与互补RNA和DNA寡聚物的亲和力和特异性方面的有价值的改进。这种新型的LNA修饰的寡核苷酸以及LNA本身在广泛的诊断应用和治疗应用中非常有用。其中包括反义应用、PCR应用、链置换寡聚物、作为核酸聚合酶的底物、作为基于核苷酸的药物等。本发明还涉及这些应用。
  • OLIGONUCLEOTIDE ANALOGUES
    申请人:Wengel Jesper
    公开号:US20100279895A1
    公开(公告)日:2010-11-04
    The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.
    本发明涉及新型的双环和三环核苷酸和核苷酸类似物,以及包含这些元素的寡核苷酸。这些核苷酸类似物,即LNAs(锁定核苷酸类似物),能够为寡核苷酸提供与互补RNA和DNA寡聚物相比亲和力和特异性的有价值的改进。这种新型的LNA修饰的寡核苷酸以及LNAs本身在广泛的诊断应用和治疗应用中都有用途。其中可以提到反义应用、PCR应用、链位移寡聚物、作为核酸聚合酶底物、作为核苷酸基药物等。本发明还涉及这些应用。
  • Oligonucleotide Analogues
    申请人:WENGEL Jesper
    公开号:US20110245327A1
    公开(公告)日:2011-10-06
    The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs ( L ocked N ucleoside A nalogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.
    本发明涉及新型的双环和三环核苷酸和核苷酸类似物,以及包含这些元素的寡核苷酸。核苷酸类似物,即锁定核苷酸类似物(LNAs),能够为寡核苷酸提供有价值的改进,使其对互补的RNA和DNA寡聚体具有更高的亲和力和特异性。这种新型的LNA修饰的寡核苷酸以及LNAs本身在广泛的诊断应用和治疗应用中都很有用。其中包括反义应用、PCR应用、链置换寡聚体、作为核酸聚合酶的底物、作为基于核苷酸的药物等。本发明还涉及这些应用。
  • Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
    申请人:Exiqon A/S
    公开号:EP2253639A1
    公开(公告)日:2010-11-24
    The present application discloses a kit for the isolation, purification, amplification, detection, identification, quantification, or capture of natural or synthetic nucleic acids, the kit comprising a reaction body and LNA modified oligonucleotide(s) (oligomers) or locked nucleoside analogue(s) (LNAs), in which the oligomers/LNAs optionally are immobilised onto said reactions body. The application further discloses corresponding uses, e.g. for capture and detection of nucleic acids such as RNA or DNA; as a probe in in-situ, Southern, Dot blot, reverse Dot blot, and Northern hybridisations; in the construction of an affinity pair; as a primer in a nucleic acid sequencing reaction or primer extension reactions; as an aptamer; for the labelling of cells; to hybridise to non-protein coding cellular RNAs, such as tRNA, rRNA, snRNA and scRNA, in vivo or in-vitro; in the construction of an oligonucleotide containing a fluorophor and a quencher; or in the construction of Taqman probes or Molecular Beacons.
    本申请公开了一种用于天然或合成核酸的分离、纯化、扩增、检测、鉴定、定量或捕获的试剂盒,该试剂盒包括反应体和 LNA 修饰的寡核苷酸(寡聚体)或锁定的核苷类似物(LNA),其中寡聚体/LNA 可选择性地固定在所述反应体上。该申请还披露了相应的用途,例如用于捕获和检测核酸,如 RNA 或 DNA;作为原位杂交、Southern 杂交、点印迹杂交、反向点印迹杂交和 Northern 杂交中的探针;用于构建亲和对;作为核酸测序反应或引物延伸反应中的引物;作为适配体;用于细胞标记;在体内或体外与非蛋白编码细胞 RNA 杂交,如 tRNA、rRNA、snRNA 和 scRNA;用于构建含有荧光素和淬灭剂的寡核苷酸;或用于构建 Taqman 探针或分子信标。
  • BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES
    申请人:Exiqon A/S
    公开号:EP1015469B2
    公开(公告)日:2015-11-18
查看更多